Panel Discussion – A New Age of GMP-Manufacturing for Future mRNA Therapies

Time: 12:00 pm
day: Day One


The development and manufacturing of mRNA for use as vaccines and therapeutics have been established since emergency use authorisation of this technology for COVID-19. As more and more candidates now enter the clinic, there is a greater need to accelerate the production of mRNA to GMP standards. This discussion will delve deeper into GMP-source and level requirements to support your projects from discovery through to clinical development and fit your program requirements

  • Developing methods to ensure sufficiency of reagents, solvents, enzymes, and nucleic acids at GMP level
  • Exploring the complexities around decision making and criterion for GMP compliant products
  • How to achieve a gold standard with next generation GMP-compliant technology, accuracy and reliability for mRNA constructs and clinical phases?